Deutsche Bank AG Invests $1.63 Million in Teladoc Health, Inc. $TDOC

Deutsche Bank AG purchased a new stake in Teladoc Health, Inc. (NYSE:TDOC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 192,197 shares of the health services provider’s stock, valued at approximately $1,630,000.

Other hedge funds also recently modified their holdings of the company. Monaco Asset Management SAM bought a new stake in Teladoc Health in the 2nd quarter valued at $26,864,000. Jupiter Asset Management Ltd. raised its position in Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after purchasing an additional 1,471,631 shares during the period. Pale Fire Capital SE lifted its stake in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after purchasing an additional 1,454,288 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after acquiring an additional 1,325,106 shares during the period. Institutional investors own 76.82% of the company’s stock.

Analyst Ratings Changes

TDOC has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Bank of America lifted their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group lowered their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Citigroup cut their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Price Performance

TDOC stock opened at $6.51 on Friday. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The business’s fifty day moving average price is $7.94 and its two-hundred day moving average price is $6.64. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -6.58 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%.The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Research analysts expect that Teladoc Health, Inc. will post -0.89 EPS for the current year.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares in the company, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the transaction, the insider directly owned 110,261 shares in the company, valued at approximately $841,291.43. This represents a 6.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock valued at $299,058 over the last three months. Company insiders own 0.70% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.